Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Ertapenem and the New Logic of Resistance Research
2026-10-05
Ertapenem is more than a susceptibility-test comparator: it can help translational researchers connect PBP biology, phenotype, pharmacokinetics, and resistance-gene mobility. This thought-leadership perspective interprets recent CREC findings while defining the evidence boundaries for using Ertapenem sodium salt in antibiotic resistance research.
-
OTUD3, SLC7A11, and Sunitinib Resistance in ccRCC
2026-10-05
A 2025 Cancer Letters study identifies OTUD3-mediated stabilization of SLC7A11 as a mechanistic link between cystine metabolism, ferroptosis suppression, and sunitinib resistance in clear cell renal cell carcinoma. The findings support lipid peroxidation as an important pharmacodynamic and mechanistic readout, while also showing why malondialdehyde measurement should be interpreted alongside molecular and cell-death evidence.
-
Nuclear cGAS, Chk2, and L1 Retrotransposition
2026-10-04
A 2023 Nature Communications study identifies nuclear cGAS as a suppressor of LINE-1 retrotransposition through a CHK2–cGAS–TRIM41 pathway that destabilizes the L1 protein ORF2p. The work expands cGAS biology beyond cytosolic DNA sensing and provides a mechanistic framework for studying genome integrity in DNA damage, senescence, and cancer research.
-
Linezolid Evidence in Antimicrobial Research
2026-10-03
A source-grounded overview of Linezolid as an oxazolidinone antimicrobial, covering its ribosomal mechanism, research relevance in resistant Gram-positive infections, evidence quality, assay limitations, and the boundaries of comparison with emerging MmpL3-directed tuberculosis compounds.
-
Gut Dysbiosis, NF-κB–IL6–STAT3, and Docetaxel Resistance
2026-10-02
Zhong et al. link antibiotic-associated gut dysbiosis to prostate cancer progression and Docetaxel resistance through increased permeability, intratumoral lipopolysaccharide, and NF-κB–IL6–STAT3 signaling. The study combines mouse tumor models, fecal microbiota transplantation, 16S rRNA profiling, mechanistic assays, and patient samples to connect microbiome composition with treatment-relevant disease behavior.
-
Carbapenemase Gene Transmission in CREC, 2022–2024
2026-10-01
This study integrates gene localization, plasmid conjugation, mobile genetic element profiling, and strain typing to examine carbapenemase dissemination in carbapenem-resistant Enterobacter cloacae across eight Guangdong teaching hospitals. Its findings identify dominant blaNDM-1 carriage, frequent transferability, and multidrug resistance as interconnected priorities for antimicrobial resistance research and hospital infection-control modeling.
-
Cefiderocol Activity in Resistant European Non-Fermenters
2026-10-01
This European surveillance study directly compared cefiderocol with newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa and Acinetobacter spp., including meropenem-resistant isolates. Cefiderocol retained high in vitro susceptibility across resistant subsets, while genomic findings implicated iron-uptake pathway changes in many cefiderocol-resistant isolates and support parallel susceptibility testing rather than assumptions based on cross-resistance.
-
Idoxuridine Workflows for Viral DNA Research
2026-09-30
Idoxuridine provides a mechanistically grounded way to interrogate viral DNA synthesis, but reliable results depend on stock handling, matched vehicle controls, and orthogonal genome, infectivity, and cell-health readouts. This workflow also adapts a rapid, reversible perturbation strategy from human neuron research without implying that the pain study validates antiviral activity.
-
Cefoperazone Sodium Salt for Resistance Assays
2026-09-30
Cefoperazone sodium salt supports reproducible MIC, MBC, β-lactamase stability, and biliary tract infection research workflows. This guide translates comparative antimicrobial evidence into practical assay design, formulation controls, and troubleshooting decisions for gram-negative bacterial resistance studies.
-
5-(N,N-dimethyl)-Amiloride in Endothelial Assays
2026-09-29
Use 5-(N,N-dimethyl)-Amiloride hydrochloride to separate Na+/H+ exchanger-dependent pH and sodium flux from downstream endothelial barrier injury. This workflow pairs DMA with moesin, permeability, and signaling readouts for more informative sepsis and cardiovascular research.
-
Mouse Neutrophil Cell Isolation Kit for Tumor Assays
2026-09-29
Build cleaner neutrophil assays for tumor immunology, cytokine response studies, and mRNA nanovaccine validation. Negative selection removes labeled unwanted cells while leaving target neutrophils untouched, supporting high-purity, function-focused experiments.
-
From CRISPR Hits to Host-State Biology in Brucella
2026-09-28
A translational framework for moving from host-gene discovery in Brucella infection to experimentally controlled macrophage-state perturbation with SDF-1beta (CXCL12), human recombinant.
-
Nitrocefin Assays for β-Lactamase Research
2026-09-28
Nitrocefin turns β-lactamase activity into a rapid yellow-to-red signal, making it useful for enzyme characterization and first-pass inhibitor screening. This guide shows how to build a controlled assay, interpret results cautiously, and apply the readout to emerging resistance research such as GOB-38 in Elizabethkingia anophelis.
-
Aztreonam Workflows for Gram-Negative Research
2026-09-27
Build reproducible Gram-negative research assays with Aztreonam, a monocyclic β-lactam antibiotic suited to studying bacterial cell-wall inhibition and resistance phenotypes. Practical guidance covers solution preparation, exploratory susceptibility workflows, assay controls, and the limits of translating preclinical findings across experimental systems.
-
BML-277 and the CHK2–cGAS Genome-Integrity Axis
2026-09-26
Explore how BML-277, a potent Chk2 inhibitor, can help researchers test the connection between DNA damage signaling and nuclear cGAS control of LINE-1 activity. This article translates a recent mechanistic discovery into cautious, testable assay strategies while distinguishing established findings from hypotheses.